We are live on ! Find out more
IDYA icon

IDEAYA Biosciences

204 hedge funds and large institutions have $2.04B invested in IDEAYA Biosciences in 2025 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 78 increasing their positions, 74 reducing their positions, and 31 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more funds holding in top 10

Funds holding in top 10: 34 (+1)

32% more capital invested

Capital invested by funds: $1.54B → $2.04B (+$493M)

3.3% more ownership

Funds ownership: 107.24%110.54% (+3.3%)

5% more repeat investments, than reductions

Existing positions increased: 78 | Existing positions reduced: 74

0% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 31

1% less funds holding

Funds holding: 207204 (-3)

68% less call options, than puts

Call options by funds: $887K | Put options by funds: $2.77M

Holders
204
Holders Change
-3
Holders Change %
-1.45%
% of All Funds
2.69%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.05%
New
31
Increased
78
Reduced
74
Closed
31
Calls
$887K
Puts
$2.77M
Net Calls
-$1.89M
Net Calls Change
-$2.73M
Name Holding Trade Value Shares
Change
Change in
Stake
NIM
76
NEOS Investment Management
Connecticut
$1.46M +$259K +13,490 +24%
TE
77
Tema ETFs
New York
$1.46M +$259K +13,490 +24%
Man Group
78
Man Group
United Kingdom
$1.43M +$1.04M +54,232 +393%
Millennium Management
79
Millennium Management
New York
$1.4M -$9.23M -480,951 -88%
FA
80
Fountainhead AM
New Jersey
$1.36M
State of Wisconsin Investment Board
81
State of Wisconsin Investment Board
Wisconsin
$1.36M -$96.4K -5,023 -7%
AssetMark Inc
82
AssetMark Inc
California
$1.32M +$246K +12,836 +26%
Citigroup
83
Citigroup
New York
$1.3M -$1.97M -102,724 -62%
Verition Fund Management
84
Verition Fund Management
Connecticut
$1.28M -$499K -26,006 -30%
NRD
85
Nebula Research & Development
New York
$1.28M -$552K -28,791 -32%
BNP Paribas Financial Markets
86
BNP Paribas Financial Markets
France
$1.24M -$1.25M -65,011 -52%
UOC
87
UBS O'Connor
Illinois
$1.08M -$343K -17,874 -26%
Mirae Asset Global ETFs Holdings
88
Mirae Asset Global ETFs Holdings
Hong Kong
$1.08M -$111K -5,760 -10%
BFM
89
Boothbay Fund Management
New York
$1.07M +$976K +50,891 New
DekaBank Deutsche Girozentrale
90
DekaBank Deutsche Girozentrale
Germany
$1.07M
MIM
91
MetLife Investment Management
New Jersey
$1.05M
AA
92
ALPS Advisors
Colorado
$993K -$274K -14,295 -23%
BCI
93
Brinker Capital Investments
Pennsylvania
$938K +$163K +8,514 +24%
Ameriprise
94
Ameriprise
Minnesota
$850K -$4.39M -228,614 -85%
IIM
95
INTECH Investment Management
Florida
$830K -$391K -20,390 -34%
ECM
96
ExodusPoint Capital Management
New York
$814K +$743K +38,720 New
HSBC Holdings
97
HSBC Holdings
United Kingdom
$804K -$908K -47,301 -56%
Squarepoint
98
Squarepoint
New York
$786K -$996K -51,937 -58%
Wellington Management Group
99
Wellington Management Group
Massachusetts
$753K -$12.5K -651 -2%
TD Asset Management
100
TD Asset Management
Ontario, Canada
$736K

IDYA Hedge Fund Activity: Q2 2025 in Review

204 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in IDEAYA Biosciences (IDYA) for Q2 2025, worth a combined $2.04B — up 32% from $1.54B a quarter earlier.

Fund positioning in IDYA was balanced in Q2 2025: 31 funds opened new positions, 31 closed out, 78 added to existing stakes and 74 trimmed.

The largest buyer was Point72 Asset Management, adding an estimated $93.8M. The largest seller was T. Rowe Price Associates, cutting an estimated $30.1M.

  • 204 institutional investors held IDEAYA Biosciences (IDYA) as of Q2 2025, down from 207 in Q1 2025.
  • Funds reported $2.04B of IDEAYA Biosciences stock for Q2 2025, up 32% quarter-over-quarter.
  • 31 funds opened new IDEAYA Biosciences positions in Q2 2025 and 31 closed out, a net change of 0 holders.
  • The largest IDEAYA Biosciences buyer in Q2 2025 was Point72 Asset Management, an estimated $93.8M added.
  • The largest IDEAYA Biosciences seller in Q2 2025 was T. Rowe Price Associates, an estimated $30.1M sold.

Based on aggregated 13F filings for Q2 2025.